TOM1L2 and metabolic syndrome: Furthermore, these 18 patients with MetS prior to CBCT showed a larger decrease in methylation of AC090023, NCAM2 and TOM1L2 one year after CBCT, compared to patients who did not have MetS before this treatment (Fig. 3B); (-11.6% (-15.3 – -8.5) vs. -8.2% (-10.4 – -5.7), p = 0.007), (-6.5% (-19.4 – -1.6) vs. -1.6% (-7.3 – 0.9), p = 0.048) and (-5.8% (-7.4 – -3.5) vs. -2.6 (-4.5 – − 0.9), p = 0.004), respectively.